OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) traded up 3.5% on Monday . The stock traded as high as $10.65 and last traded at $10.52, with a volume of 198,763 shares traded. The stock had previously closed at $10.16.

Several equities research analysts recently weighed in on the stock. Mizuho reduced their price target on shares of OncoMed Pharmaceuticals from $45.00 to $40.00 and set a “neutral” rating on the stock in a research report on Wednesday, June 1st. Cantor Fitzgerald restated a “buy” rating on shares of OncoMed Pharmaceuticals in a research report on Wednesday, June 8th. Jefferies Group restated a “buy” rating and issued a $15.00 price target (down previously from $16.00) on shares of OncoMed Pharmaceuticals in a research report on Friday, May 6th. Zacks Investment Research cut shares of OncoMed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 10th. Finally, Leerink Swann boosted their price target on shares of OncoMed Pharmaceuticals from $11.00 to $13.00 and gave the stock a “market perform” rating in a research report on Thursday, May 5th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $19.29.

The stock’s market cap is $337.68 million. The firm’s 50-day moving average price is $12.07 and its 200-day moving average price is $11.50.

OncoMed Pharmaceuticals (NASDAQ:OMED) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.81) by $0.10. During the same quarter last year, the firm earned ($0.72) earnings per share. The firm had revenue of $6.67 million for the quarter, compared to analyst estimates of $8.09 million. OncoMed Pharmaceuticals’s revenue for the quarter was up 42.2% on a year-over-year basis. On average, equities analysts expect that OncoMed Pharmaceuticals Inc. will post ($3.39) EPS for the current fiscal year.

An institutional investor recently bought a new position in OncoMed Pharmaceuticals stock. Jennison Associates LLC bought a new position in shares of OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 89,546 shares of the biopharmaceutical company’s stock, valued at approximately $2,018,000. Jennison Associates LLC owned 0.30% of OncoMed Pharmaceuticals at the end of the most recent quarter.

OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.